Department of Gastroenterological Surgery, Minoh City Hospital, Kayano 5-7-1, Minoh, Osaka, 562-0014, Japan.
Int J Colorectal Dis. 2019 Nov;34(11):1933-1943. doi: 10.1007/s00384-019-03413-z. Epub 2019 Oct 30.
Whether malignant colorectal obstruction (MCO) after one-stage curative surgery without preoperative decompression has a poor prognosis remains unclear. We assessed long-term outcomes of one-stage surgery without preoperative decompression for stage II/III MCO.
We retrospectively enrolled patients with stage II/III colorectal cancer (CRC) between April 2011 and December 2017. Propensity score-matched (PSM) analysis was used to reduce the possibility of selection bias.
In total, 464 stage II/III CRC patients were identified, of which 145 (31%) had obstruction (MCO group) and 319 (69%) did not (non-MCO group). In the MCO group, 59 (40.7%) had emergency MCO (E-MCO) and 86 (59.3%) had semi-emergency MCO (SE-MCO). The median follow-up was 37.0 (range 0-86.5) months. The tumor was deeper and larger, and serum carcinoembryonic antigen level was higher (p < 0.001, respectively) in the MCO group (including E-MCO and SE-MCO). Venous invasion-positivity rate was significantly higher (MCO and SE-MCO only, p = 0.003 and 0.009, respectively) than that in the non-MCO group. Laparoscopic surgery rate was significantly lower (MCO and E-MCO only, p < 0.001) than that in the non-MCO group. Before PSM, disease-free survival (DFS) of the SE-MCO patients was worse than that of the non-MCO patients (p = 0.046). After PSM, DFS was not significantly different between the non-MCO and MCO, E-MCO, and SE-MCO groups (p = 0.619, 0.091, and 0.308, respectively).
Long-term prognosis in patients with stage II/III MCO after one-stage surgery without preoperative decompression was similar to that in patients without MCO.
一期无术前减压根治术后合并恶性结直肠梗阻(MCO)的患者预后是否较差仍不清楚。我们评估了一期手术无术前减压治疗 II/III 期 MCO 的长期疗效。
我们回顾性纳入了 2011 年 4 月至 2017 年 12 月期间 II/III 期结直肠癌(CRC)患者。采用倾向评分匹配(PSM)分析以降低选择偏倚的可能性。
共纳入 464 例 II/III 期 CRC 患者,其中 145 例(31%)合并梗阻(MCO 组),319 例(69%)未合并梗阻(非 MCO 组)。在 MCO 组中,59 例(40.7%)为急诊 MCO(E-MCO),86 例(59.3%)为择期 MCO(SE-MCO)。中位随访时间为 37.0(0-86.5)个月。MCO 组(包括 E-MCO 和 SE-MCO)的肿瘤更深更大,血清癌胚抗原水平更高(p < 0.001),静脉侵犯阳性率也明显更高(仅在 MCO 和 SE-MCO 中,p = 0.003 和 0.009)。腹腔镜手术率明显低于非 MCO 组(仅在 MCO 和 E-MCO 中,p < 0.001)。PSM 前,SE-MCO 患者的无病生存率(DFS)较非 MCO 患者差(p = 0.046)。PSM 后,非 MCO 组与 MCO 组、E-MCO 组和 SE-MCO 组之间的 DFS 无显著差异(p = 0.619、0.091 和 0.308)。
一期无术前减压根治术后合并恶性结直肠梗阻患者的长期预后与无 MCO 患者相似。